WaveMan
WaveMan · Company
BYSI · Beyondspring Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

BYSI BeyondSpring (BYSI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001677940
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter

BeyondSpring insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for BeyondSpring Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Decheng Capital China Life Sciences USD Fund II, L.P.
SELL
2025-10-20 SECtraded 2025-10-17
45,513
$80.1K
-79.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Oct 16, 2025.
  • The trade is 3.0% of the 1,518,893 shares held after it.
  • 3 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Decheng Capital China Life Sciences USD Fund II, L.P. sold about $80.1K of BYSI on Oct 17, 2025; 3 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
Decheng Capital China Life Sciences USD Fund II, L.P.
SELL
2025-10-20 SECtraded 2025-10-16
85,798
$147.6K
-79.0%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Aug 28, 2025.
  • The trade is 5.5% of the 1,564,406 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Decheng Capital China Life Sciences USD Fund II, L.P. sold about $147.6K of BYSI on Oct 16, 2025; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
Decheng Capital Global Healthcare GP, LLC
SELL
2025-10-15 SEC
17,960
$29.6K
-74.1%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Oct 14, 2025.
  • The trade is 1.1% of the 1,650,204 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Decheng Capital Global Healthcare GP, LLC sold about $29.6K of BYSI on Oct 15, 2025; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
Decheng Capital Global Healthcare GP, LLC
SELL
2025-10-15 SECtraded 2025-10-14
28,495
$47.0K
-74.1%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Oct 13, 2025.
  • The trade is 1.7% of the 1,668,164 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Decheng Capital Global Healthcare GP, LLC sold about $47.0K of BYSI on Oct 14, 2025; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
Decheng Capital Global Healthcare GP, LLC
SELL
2025-10-15 SECtraded 2025-10-13
107,361
$182.5K
-74.1%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Oct 10, 2025.
  • The trade is 6.3% of the 1,696,659 shares held after it.
  • 4 other insiders sold within 30 days.
  • 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Decheng Capital Global Healthcare GP, LLC sold about $182.5K of BYSI on Oct 13, 2025; 4 other insiders sold within 30 days and 9 funds added in the latest 13F quarter.
63 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 58 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
7.7% of the float short (float per yahoo 2026-10-26) · 2.5 days to cover · settled 2026-09-30
more than 56% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch BYSI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-77.1%12M
-79%-47%-15%+16%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BYSI: institutional holders (13F)

13F holdings, latest reported quarter
Decheng Capital LLC
3,800,702 sh
$6.7M
BlackRock, Inc.
672,915 sh
$1.2M
VANGUARD CAPITAL MANAGEMENT LLC
626,457 sh
$1.1M
GEODE CAPITAL MANAGEMENT, LLC
367,740 sh
$643.9K
STATE STREET CORP
231,120 sh
$404.5K

Congress trades in BYSI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BYSI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

BYSI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
VANGUARD EXTENDED MARKET INDEX FUND
$600.4K position · as of 2026-06-30
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$494.7K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BYSI financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$16.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
n/a
no debt to cover
Return on equity
n/a
average equity is zero or negative
Return on assets
-29.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-84.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$16.3M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2021-12-31 (54 months older than the period end) plus current 2022-12-31 (42 months older than the period end), minus cash 2026-06-30
FCF yield
-88.1%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$0$0$0$1.4M
Operating income-$8.9M-$8.8M-$15.1M-$37.2M
Net income-$1.0M-$11.1M-$21.0M-$33.3M
Operating cash flow-$19.8M-$16.4M-$16.5M-$27.5M
Cash$7.8M$2.9M$5.4M$34.4M
SEC XBRL, fiscal years, as known on 2026-10-28

BYSI Stock Sonar score 3/7 axes

Find similar shapesCompare

BYSI ranks highest on risk and compliance (70th percentile) and profitability (46th), and lowest on institutional and government (14th), among Pharma & Biotech peers.

Profitability
46
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-29.3% · 61 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-84.6% · 31 pct, sector of 576
Institutional and government
14
Inputs
  • Funds adding, latest quarter9 · 14 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
70
Inputs
  • Short interest, % of float+7.7% · 47 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+2.4% · 94 pct, sector of 511
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; no debt to cover
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies